CJC1295, Ipamorelin, GHRP-2

Like the platform's other CJC-1295 listings that don't specify DAC status in the name, researchers should confirm with the supplier whether the CJC-1295 in this three-peptide blend includes the Drug Affinity Complex modification - DAC-conjugated CJC-1295 produced multi-day elevated GH and IGF-1 secretion in Teichman et al.'s human study, while non-DAC CJC-1295 (Mod GRF 1-29) behaves closer to short-half-life native GHRH, and the two are not interchangeable in a study protocol. The second design question is independent of DAC status: ipamorelin and GHRP-2 both act at the ghrelin receptor (GHS-R1a) rather than at complementary receptors, differing mainly in selectivity - ipamorelin was characterized for minimal ACTH/cortisol/prolactin co-release in its founding study, while GHRP-2 is documented to produce more of that co-release - so this blend combines a selective and a less-selective agonist at the same receptor alongside the GHRH-pathway peptide. Researchers using this combination should treat it as two open variables (DAC status, GHS-R1a receptor overlap) rather than a single well-defined three-part mechanism.

Potential Research Applications: DAC-status verification and formulation-confirmation research GHS-R1a receptor-competition research between co-agonists of differing selectivity Dual-pathway (GHRH + ghrelin receptor) pituitary stimulation studies Comparative pharmacokinetic research across CJC-1295 variants

What the Founding Studies Reported

CJC-1295 with DAC: in two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults (ages 21–61), a single subcutaneous injection produced dose-dependent increases in mean plasma GH of 2- to 10-fold for six days or more and in IGF-I of 1.5- to 3-fold for 9–11 days, with an estimated half-life of 5.8–8.1 days. After multiple doses, mean IGF-I stayed above baseline for up to 28 days. That multi-day profile is what distinguishes the DAC-conjugated form from Mod GRF 1-29, and it is why DAC status changes the sampling schedule of any experiment built on this blend.

Ipamorelin: the 1998 characterization identified the pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) from a series lacking the central Ala-Trp of GHRP-1. It released GH from primary rat pituitary cells with potency similar to GHRP-6 (EC50 1.3 nmol/L) and acted through a GHRP-like receptor, as shown with GHRP and GHRH antagonists. In the same study, GHRP-2 displayed higher potency but lower efficacy than ipamorelin in conscious swine (ED50 0.6 nmol/kg; Emax 56 ng GH/mL versus 65 ng/mL). Ipamorelin's specificity for GH release, without the ACTH, cortisol, or prolactin co-release seen with other secretagogues, was the study's headline finding.

GHRP-2 (pralmorelin): an orally active synthetic GH-releasing peptide from the Bowers series that mimics ghrelin. Its established use is diagnostic. It markedly raises plasma GH in healthy subjects regardless of sex, obesity, or age, and the blunted response in GH-deficient patients gives a receiver-operating-characteristic cut-off (GH peak 15.0 μg/L) for identifying GH deficiency. A 2026 narrative review in the American Journal of Sports Medicine that evaluated CJC-1295 + ipamorelin among injectable peptides found the human evidence base thin.

Live Market Data on Peptides.SO (listing data on file as of 13 September 2026)

Peptides.SO currently tracks 2 listings for the CJC-1295 / Ipamorelin / GHRP-2 blend, both from Peptides World, at $89.90 and $109.90 (per-mg pricing on the listings for the combined vial). The median list price across the 1,536 priced listings in the platform's growth-peptides category is $60.99, so the two blend listings sit roughly 47% and 80% above the category midpoint — expected for a three-component vial versus single-peptide listings. For a price benchmark on the components, the CJC-1295 page, ipamorelin page, and GHRP-2 page each aggregate every supplier on the platform. No supplier on the platform currently has a testing score or certificate-of-analysis link on file, so DAC status and the three individual peptide masses should be confirmed from the vendor's lot documentation.

Frequently Asked Questions

Why combine two ghrelin-receptor agonists? There is no published study of ipamorelin plus GHRP-2 in the same preparation. Both act at GHS-R1a, so the second agonist adds receptor competition rather than a new pathway; a blend with only one of them is easier to interpret.

Does GHRP-2 in the blend defeat ipamorelin's selectivity? Potentially. Ipamorelin's defining feature was GH release without ACTH/cortisol/prolactin co-release; GHRP-2 does not share that selectivity to the same degree, so the combined preparation should not be assumed to be selective.

Is the CJC-1295 here DAC or non-DAC? The listing name does not specify. Ask the supplier; the two forms have half-lives that differ by more than an order of magnitude.

Related Pages on Peptides.SO

Background reading: the CJC-1295 DAC vs no-DAC comparison, the ipamorelin vs GHRP-2 comparison, and the GHRP-2 research profile. Model single-agent versus combined arms in the Stack Builder.

Cited Research

Teichman SL et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683

Raun K et al.. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822

Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004. PubMed 15230633

Mayfield CK et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PubMed 41476424

For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.